U.S. Banks Stock News

If you are wondering whether QuidelOrtho's current share price reflects its underlying value, this article walks through the key numbers that investors tend to focus on before making a decision. QuidelOrtho last closed at US$15.88, with returns of 4.1% over the past week, a 23.8% decline over the past month, and year to date and 1 year returns of 44.8% and 44.0% declines respectively. The 3 year and 5 year returns sit at 82.5% and 87.5% declines. These moves come as investors reassess the...

Amdocs recently extended its long-term relationship with T-Mobile under a new multi-year agreement covering managed services, software development, and AI innovation, while also expanding its engagement with Vodafone Germany, adding two western European clients, completing the Matrixx Software acquisition, and unveiling its telecom-focused aOS agentic operating system. Together, these moves point to Amdocs deepening its role at large carriers and broadening its telecom software capabilities...

Wondering if Gentex at around US$21.50 is genuinely good value or just looks cheap on the surface? This article walks through the key signals that matter for you. The stock has returned 0.5% over the last 7 days, while the 30 day and year to date returns of a 2.6% decline and a 9.2% decline contrast with a 1 year gain of 2.6%, and a 3 year and 5 year decline of 17.1% and 35.1%. Recent coverage has focused on how Gentex fits within the auto components space and what that means for sentiment...

In March 2026, Johnson & Johnson announced a US$500 million R&D co-funding agreement with Royalty Pharma across 2026 and 2027 to advance JNJ-4804, a novel co-antibody therapy targeting both IL-23 and TNF pathways in autoimmune diseases. This collaboration gives Royalty Pharma exposure to an early-stage, dual-pathway autoimmune candidate that could meaningfully influence the mix and risk profile of its royalty portfolio. Next, we’ll examine how this substantial R&D co-funding commitment...

Nova (NasdaqGS:NVMI) is back on investor radars after years of growth in revenue and earnings per share, coupled with strong free cash flow margins that underline its position in semiconductor process control. See our latest analysis for Nova. Novoa’s recent share price momentum has been strong, with a 7 day share price return of 7.82% and a year to date share price return of 28.27%. The 1 year total shareholder return of 161.15% shows how powerfully sentiment has shifted over a longer...

In its fourth-quarter 2025 investor letter, TimesSquare Capital’s U.S. Small Cap Growth Strategy highlighted NewAmsterdam Pharma’s CETP inhibitor program for cardiovascular patients, citing strongly positive indications ahead of trial readouts. This attention underscores how emerging data around LDL-lowering CETP inhibitors can quickly elevate a smaller biopharma company’s profile within the cardiovascular treatment landscape. We’ll now examine how growing optimism around NewAmsterdam...

The United States market has experienced a notable upswing, climbing 4.4% in the last week and an impressive 32% over the past year, with earnings projected to grow by 16% annually. In this environment, identifying stocks that may be undervalued requires a keen eye for potential growth and resilience amidst broader market gains, as highlighted by companies like BillionToOne and others.

The market has climbed 4.4% in the last 7 days and is up 32% over the last 12 months, reflecting strong investor confidence. For those looking to invest in smaller or newer companies, penny stocks—despite their somewhat outdated name—can still offer surprising value when backed by solid financial foundations. This article highlights several penny stocks that demonstrate financial strength and potential for long-term growth amidst current market conditions.

The United States market has shown impressive momentum, with a 4.4% increase over the last week and a remarkable 32% gain over the past year, while earnings are projected to grow by 16% annually. In this dynamic environment, identifying small-cap stocks with strong potential can offer unique opportunities for investors seeking to capitalize on emerging growth stories within the market.

Over the last 7 days, the United States market has risen by 4.4%, contributing to a remarkable 32% increase over the past year, with earnings projected to grow by 16% annually. In this thriving environment, identifying strong dividend stocks like First Financial Bancorp and others can offer investors a reliable income stream and potential for growth amidst favorable market conditions.

Pinnacle Financial Partners recently expanded its Louisville Lakeview office by hiring David Krebs, a veteran commercial banker with more than 25 years of relationship-management experience from Stock Yards Bank & Trust. At the same time, fresh analysis points to rising expenses, a relatively low 3.2% net interest margin and slowing tangible book value growth, prompting questions about how efficiently Pinnacle can convert its sizeable US$877.4 million net cash position into sustainable...

HCI Group recently reported a strong Q4, with revenues rising 52.1% year on year, beating analyst expectations and capping a year of record 2025 earnings and shareholder returns, alongside the successful IPO of its technology platform, Exzeo. The combination of rapidly growing revenue and the separation of Exzeo as a listed technology platform raises fresh questions about how HCI Group’s business mix and earnings profile could evolve. Next, we’ll examine how HCI Group’s record 2025 earnings...

In 2025, former H2O America President, CEO, and Chairman Eric W. Thornburg received total compensation of US$3,065,270, while the current CEO recently sold shares on the open market and institutional investors shifted their holdings. At the same time, short interest in H2O America jumped very large in March, with a significant portion of shares now sold short, pointing to a sharper focus on potential operational or financial issues. Analyst Ross Fowler at BofA Securities continues to rate...

In March 2026, Bio-Techne expanded its COMET spatial biology portfolio with new SPYRE Focus Panels, SPYRE Amplification Kits, and upgraded HORIZON image analysis software to enhance automated, modular tissue analysis workflows from assay design through interpretation. This expansion deepens Bio-Techne’s footprint in high-content spatial biology by combining validated, modular antibody panels with seqLA-based signal amplification to help researchers extract richer insights from scarce tissue...

Why Regencell Bioscience Holdings (NasdaqCM:RGC) is in Focus Right Now Regencell Bioscience Holdings (NasdaqCM:RGC) has filed a US$500 million follow on equity offering of common stock as an at the market program, shortly after registering a shelf for its ordinary shares. See our latest analysis for Regencell Bioscience Holdings. The equity offering headlines come after a sharp shift in sentiment, with a 7 day share price return of 32.15% and a 30 day share price return of 32.03%, set against...

Nelnet, Inc. recently entered into a new Credit Agreement for a US$435 million unsecured line of credit maturing on March 31, 2031, while terminating its prior US$495 million facility that was due in 2026 and carried no outstanding balance at the time. This refreshed, long-dated borrowing capacity, backed by customary financial covenants and subsidiary guarantees, underscores the company’s emphasis on maintaining flexible funding for general corporate purposes. With this extended US$435...

Recently, HF Sinclair reported quarterly earnings of US$1.20 per share, very large above the consensus estimate of US$0.44, extending a multi-quarter pattern of outperforming analyst expectations. This repeated earnings outperformance has led analysts to grow more optimistic about the company’s near‑term profit potential, especially given its integrated refining and fuel production footprint. Building on this recent history of substantial earnings surprises, we’ll explore how strengthened...

In March 2026, ICON plc and Advarra announced a partnership to create a connected, “research-ready” site network that links ICON’s clinical trial solutions with Advarra’s widely used site technologies to reduce administrative friction, speed up study startup, and expand trial access globally. This collaboration gives ICON access to Advarra’s data and AI-driven operational intelligence, potentially refining protocol design, forecasting, and site selection by aligning studies more closely with...

Key performance context for PayPay PayPay (PAYP) has drawn attention after a 10.37% one day decline and an 8.81% drop over the past week, prompting investors to reassess its fundamentals and recent share price moves. The company reports annual revenue of ¥355,530 and net income of ¥111,208, with revenue growth of 16.82% and net income growth of 5.77% in the most recent year, all in its reporting currency. See our latest analysis for PayPay. The recent 10.37% one day share price return decline...

Why Maase Has Caught Investor Attention Recent trading interest in Maase (MAAS) has pushed the stock into focus, with short term performance and fundamentals prompting investors to reassess how this US listed China based financial services platform fits into their portfolios. See our latest analysis for Maase. At a share price of $5.90, Maase has seen a 7 day share price return of 8.26% and a 90 day share price return of 13.24%, suggesting recent momentum is building after a relatively modest...

FIHL stock moves and recent financial snapshot Fidelis Insurance Holdings (FIHL) has seen its share price show modest short term moves, with a 1 day return of 0.78% and a past month return of 3.6%. These recent moves may prompt some investors to take a closer look at its fundamentals. The company reports annual revenue of US$2,500.5m and net income of US$225.5m. This implies a net margin figure that investors can compare with other insurers. Annual revenue growth is reported at 11.7%, with...

If you are wondering whether Watts Water Technologies is priced attractively at its recent levels, the starting point is understanding what the current market price is implying about its future. The share price recently closed at US$287.95, with returns of 1.5% over 7 days, a 5.9% decline over 30 days, 3.4% year to date, 58.6% over 1 year, 87.8% over 3 years, and 151.1% over 5 years. Recent coverage of the company has focused on its role within capital goods and water-related solutions. This...

In recent months, the Pennsylvania Public Utility Commission held public hearings and suspended UGI Utilities’ proposed natural gas distribution rate increase, which sought an 8.05% rise in annual operating revenues and would have lifted typical residential bills by about 8–9% to fund infrastructure, cybersecurity, and IT upgrades. This regulatory pushback highlights how strongly public sentiment and oversight can influence UGI’s ability to recover investment spending through higher rates, a...

Immunovant (IMVT) is back in focus after reporting that two Phase 3 studies of batoclimab in thyroid eye disease did not meet their primary endpoint, prompting a shift in attention toward its IMVT-1402 program. See our latest analysis for Immunovant. Despite the batoclimab setback, Immunovant’s recent 1-day and 7-day share price returns of 1.59% and 5.69% suggest some near term optimism. Its 72.97% 1-year total shareholder return keeps the longer term story firmly in focus. If you are...